CurrentUnitedHealthcarePolicy CS130NM.C

Virtual Upper Gastrointestinal Endoscopy (for New Mexico Only) – Community Plan Medical Policy

This UnitedHealthcare New Mexico medical policy governs coverage determination for virtual upper gastrointestinal endoscopy (3-D CT or 3-D MRI virtual gastroscopy/virtual esophagography) including clinical rationale, evidence summary, and applicable procedure codes. It applies only to New Mexico members and provides the plan position that the procedure is unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyVirtual Upper Gastrointestinal Endoscopy (for New Mexico Only) – Community Plan Medical Policy

Policy CodePolicy CS130NM.C

Change TypeSupporting Information (Clinical Evidence updated)

Effective DateNov 1, 2025

Next Review Date

Key ActionThis Medical Policy applies only to New Mexico; providers must reference state/contractual/federal benefit requirements which may supersede this policy.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence section to reflect the most current information.

Archived previous policy version CS130NM.B; summary of changes labeled 'Supporting Information'.

0Covered Indications

2Applicable CPT Unlisted Codes Listed

2025Policy Effective Year

This UnitedHealthcare New Mexico medical policy (Policy Number CS130NM.C) governs coverage determinations for virtual upper gastrointestinal endoscopy (virtual gastroscopy/virtual esophagography) performed using three-dimensional CT or three-dimensional MRI. The policy applies only to the state of New Mexico and provides the plan position that the procedure is unproven and not medically necessary for detecting and evaluating upper GI lesions.

Policy Facts

Policy NumberCS130NM.C

Subject/TitleVirtual Upper Gastrointestinal Endoscopy (3-D CT or MRI) for New Mexico

PayerUnitedHealthcare

ScopeNew Mexico only

Policy Effective DateNovember 1, 2025

Policy StatusCURRENT

Policy Effective Year2025

Medical Necessity Determination

Virtual upper GI endoscopy is considered not medically necessary when used to detect or evaluate upper GI lesions because evidence is insufficient.

Procedure is virtual upper gastrointestinal endoscopy using three-dimensional computed tomography (3-D CT) or three-dimensional magnetic resonance imaging (3-D MRI).
Indication is detection and/or evaluation of upper GI lesions (examples: nausea, gastric reflux, abdominal pain, unexplained weight loss; identifying esophageal varices, inflammation, ulcers, precancerous conditions, hernias; gastric cancer preoperative staging).
Coverage Determination: There is insufficient evidence of efficacy (no randomized controlled trials; primarily observational and technical studies); therefore the procedure is unproven and not medically necessary.

Not Medically Necessary / Unproven Uses

The policy states that virtual upper GI endoscopy using 3-D CT or 3-D MRI is considered not medically necessary for the detection or evaluation of upper GI lesions because there is insufficient evidence of efficacy. Indications discussed in the policy include symptom evaluation (for example, nausea, gastric reflux, abdominal pain, unexplained weight loss) and assessment or identification of conditions such as esophageal varices, inflammation, ulcers, precancerous conditions, hernias, and use in gastric cancer preoperative staging.

The evidence section notes that the published literature is primarily observational and technical in nature with no randomized controlled trials identified. Diagnostic performance studies exist but are limited by study design and size. Examples cited include Kumar et al. (2023) and Kim et al. (2012) as illustrative diagnostic performance reports and as examples of the observational/technical nature of the evidence base.

Applicable Codes

Applicable procedure codes (reference only)CPT

76497	Unlisted computed tomography procedure (e.g., diagnostic, interventional)
76498	Unlisted magnetic resonance procedure (e.g., diagnostic, interventional)

FDA product codes (informational)mixed

JAK	FDA product code - imaging devices used to create virtual endoscopy images (informational)
LLZ	FDA product code - imaging devices used to create virtual endoscopy images (informational)
LNH	FDA product code - imaging devices used to create virtual endoscopy images (informational)

Provider Actions & Billing Impact

Denial Risk

Not medically necessary position

Claims for virtual upper GI endoscopy (3-D CT or 3-D MRI) to detect or evaluate upper GI lesions are considered unproven and not medically necessary under this policy and are subject to denial.

76497
76498

Documentation Required

State applicability

This medical policy applies only to the state of New Mexico. Providers must reference applicable state, contractual, and federal benefit requirements, which may supersede this policy.

Documentation Required

When lesion found

If a lesion is identified on virtual endoscopy, conventional upper GI endoscopy is necessary to obtain biopsy specimens. Providers should document the planned follow-up (including referral for standard endoscopy) and code invasive diagnostic or therapeutic endoscopic procedures using the standard endoscopy procedure codes.

Background and Evidence Summary

Virtual upper GI endoscopy is a noninvasive imaging technique that reconstructs the mucosal surfaces of the upper GI tract using 3-D CT or 3-D MRI. Advantages include being noninvasive and typically not requiring anesthesia or sedation. Disadvantages include limited fine detail compared with conventional endoscopy, exposure to CT radiation when CT is used, and the inability to perform biopsy during the virtual procedure; if a lesion is identified, conventional upper GI endoscopy is required for biopsy.

Evidence base: The literature evaluating virtual upper GI endoscopy consists largely of observational studies, case reports, and technical feasibility reports; no randomized controlled trials have been identified. Studies are frequently single-center, retrospective, and include small participant numbers, limiting conclusions about clinical utility and long-term outcomes.

Diagnostic performance examples: Selected studies report variable sensitivity and specificity. For example, Kumar et al. (2023) reported CT virtual esophagography sensitivity of 86% and specificity of 90% for grading esophageal varices, while Kim et al. (2012) reported virtual gastroscopy sensitivities up to 95.1% for certain reconstructions compared with 2-D axial CT. Other studies report reasonably high accuracy for T staging in gastric cancer (e.g., Wani et al. 2021: T staging accuracy ~82.5%) but also note limitations such as small samples, retrospective design, and lack of RCTs demonstrating impact on patient outcomes.

Definitions

TermVirtual upper gastrointestinal endoscopy

DefinitionNoninvasive imaging procedure using 3-D CT or 3-D MRI reconstructions (virtual gastroscopy/virtual esophagography) to visualize mucosal surfaces of the upper GI tract.

Revision History

2025-11-01policy_revisionLatest

Archived previous policy version CS130NM.B; summary of changes labeled 'Supporting Information'. Updated Clinical Evidence section to reflect the most current information. Change classified as non-material (is_material=false).

Policy Summary

PayerUnitedHealthcare

PolicyVirtual Upper Gastrointestinal Endoscopy (for New Mexico Only) – Community Plan Medical Policy

Policy CodePolicy CS130NM.C

Change TypeSupporting Information (Clinical Evidence updated)

Effective DateNov 1, 2025

Next Review Date

Key ActionThis Medical Policy applies only to New Mexico; providers must reference state/contractual/federal benefit requirements which may supersede this policy.

SourceLink

On This Page

OpenPayer

Virtual Upper Gastrointestinal Endoscopy (for New Mexico Only) – Community Plan Medical Policy

Coverage Summary

Medical Necessity Determination

Not Medically Necessary / Unproven Uses

Applicable Codes

Provider Actions & Billing Impact

Background and Evidence Summary

Revision History